Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05886660
- Locations
- 🇺🇸
NASA Johnson Space Center Neuroscience Laboratory, Houston, Texas, United States
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05852730
- Locations
- 🇺🇸
NASA Johnson Space Center Neuroscience Laboratory, Houston, Texas, United States
Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 503
- Registration Number
- NCT05548270
- Locations
- 🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04947423
- Locations
- 🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States
Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT04272255
- Locations
- 🇺🇸
NAMRU-D, Dayton, Ohio, United States
DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04219982
- Locations
- 🇺🇸
NAMRU-D, Dayton, Ohio, United States
Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT04184115
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT03988530
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
The Prevention and Treatment of Nausea Associated With Motion Sickness
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT03986905
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
Scopolamine in Healthy Volunteers
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Repurposed Therapeutics, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03874130
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
© Copyright 2024. All Rights Reserved by MedPath